Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Welcome to stench ground zero: The village where an unspeakable two
New York bill could repeal 1907 law that criminalizes adultery
New York bill could repeal 1907 law that criminalizes adultery
DMV experienced nationwide outage for nearly 3 hours
Growing wildfire risk leaves states grappling with how to keep property insurers from fleeing
What you need to know about investing in a VCT and the 30% tax break
Biden pledges 'relentless diplomacy' on global challenges
California's population grew in 2023, halting 3 years of decline
Do you live near one? Interactive map reveals the locations of England's 400,000 heritage sites
Workers' paychecks grew faster in the first quarter, a possible concern for the Fed
Your state pension might NOT increase by the full 8.5% this month